查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1822387

2032 年梅毒检测市场预测：按类型、检测地点、技术、分销管道、应用、最终用户和地区进行的全球分析

Syphilis Testing Market Forecasts to 2032 - Global Analysis By Type, Location of Testing, Technology, Distribution Channel, Application, End User, and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，全球梅毒检测市场预计在 2025 年达到 24.9 亿美元，预计到 2032 年将达到 44.9 亿美元，预测期内的复合年增长率为 8.8%。

梅毒检测是指旨在识别梅毒螺旋体（一种导致梅毒的细菌）感染的临床程序。诊断方法通常包括血液非梅毒螺旋体检测和梅毒螺旋体检测，有助于确定疾病分期、确诊感染并追踪患者对治疗的反应。此类检测对于限制疾病传播、保护母婴健康以及控制併发症至关重要。对于高风险族群或可能感染性行为感染传染病的族群，此类检测尤其重要。

增加常规筛检项目

梅毒筛检的日益常规化实施极大地推动了市场需求。公共卫生机构正在加强，以儘早发现感染，尤其是在孕妇和爱滋病毒阳性者等高风险族群。快速就地检验技术的进步使其能够在诊所和推广机构中广泛部署。与数位健康平台的整合正在简化患者追踪和诊断跟进。新兴趋势包括基于人工智慧的筛检演算法和基于行动装置的检测套组，从而提高了可及性。随着各国政府扩大其性传染感染监测项目，梅毒检测正成为预防性医疗保健策略的核心部分。

医疗基础设施和医疗服务不足

许多低收入国家面临训练有素的人员、检测能力和基本检测用品短缺的问题。基础设施缺口在孕产妇保健机构特别明显，而早期发现先天性梅毒至关重要。数位连结性的缺乏进一步限制了与集中式卫生系统的整合。行动诊所和远端医疗提供了部分解决方案，但扩充性仍是一项挑战。如果没有对医疗基础设施的持续投资，梅毒检测覆盖率在各地区仍将不平衡。

整合多重和双重用途测试

在临床和公共卫生领域，能够同时检测多种性传染感染的双效检测方法正变得越来越普遍。这些平台缩短了周转时间，提高了成本效益，并增强了病患的依从性。微流体和生物感测器技术的进步使得紧凑型多分析物检测设备能够实现分散式使用。监管机构越来越多地支持批量检测通讯协定，以简化医疗服务。随着个人化医疗的发展，多重梅毒检测预计将在全面的性健康筛检中发挥关键作用。

与其他性传染感染诊断的竞争

HIV、披衣菌感染和淋病检测通常占据采购预算和公共卫生优先事项的主导地位。除非多病原体检测组合能够策略性地整合，否则对梅毒专案创新的关注可能会减少。分子诊断和基于 CRISPR 的检测技术的快速发展正在将人们的注意力转移到新技术上。市场碎片化也受到地区对特定检测形式和品牌的偏好所驱动。

COVID-19的影响

疫情扰乱了常规性传染感染筛检项目，导致诊断延迟和检测减少。封锁措施以及将资源重新分配给新冠诊断工具，导致实验室能力和供应链紧张。然而，这场危机加速了远端性传染感染检测套组和数位报告平台的采用。紧急监管措施使得新型梅毒检测（包括自我检测）得以快速核准。疫情后策略如今强调韧性、分散式诊断以及与疫情防范框架的整合。

预测期内，先天性梅毒市场预计将占最大份额

由于先天性梅毒对公共卫生有重大影响，预计将在预测期内占据最大的市场份额。强制性孕产妇筛检和产前护理通讯协定的改进正在推动对早期检测工具的需求。快速梅毒螺旋体检测技术的进步使得在怀孕期间及时介入成为可能。各国政府正透过有针对性的资金和监测计画优先消除先天性梅毒。与电子健康记录的整合正在改善病例追踪和后续治疗。随着人们意识的提高，先天性梅毒检测正成为孕产妇和新生儿健康策略的基石。

预计预测期内公共卫生计画部分将以最高的复合年增长率成长。

受全球性传播感染控制倡议扩展的推动，公共卫生计画领域预计将在预测期内实现最高成长率。国家和地方的宣传活动正在透过流动单位、社区推广和学校干预措施扩大梅毒筛检。云端基础数据系统的采用正在增强专案监测和流行病学洞察。低成本、高通量检测平台的创新使大规模筛检更加可行。非政府组织、政府和诊断公司之间的伙伴关係正在加速在高负担地区的部署。随着全球卫生重点转向消除性传染感染，公共卫生计画将成为市场扩张的中心。

比最大的地区

预计亚太地区将在预测期内占据最大市场份额，这得益于医疗保健投资的增加和全民筛检工作的推进。中国、印度和印尼等国家正在透过国家卫生任务和数位健康部署扩大性传染感染诊断服务。检测套组的本地化生产正在提高可负担性和供应链的韧性。新兴趋势包括人工智慧驱动的诊断平台和专为偏远地区量身定制的行动检测实验室。全球和区域公司之间的策略合作伙伴关係正在增强技术转移和市场渗透。

复合年增长率最高的地区：

在技​​术领先地位和强大的公共卫生基础设施的推动下，北美预计将在预测期内呈现最高的复合年增长率。美国和加拿大正大力投资下一代性传染感染诊断技术，包括分子和人工智慧增强平台。监管机构正在简化创新梅毒检测的核准，包括居家医疗和远端医疗检测。与电子健康记录和预测分析的整合正在改善个案管理和疫情应对。保险报销框架越来越支持常规性传染感染筛检，尤其是在医疗资源匮乏的社区。

免费客製化服务：

此报告的订阅者可以使用以下免费自订选项之一：

  • 公司简介
    • 对最多三家其他市场公司进行全面分析
    • 主要企业的SWOT分析（最多3家公司）
  • 区域细分
    • 根据客户兴趣对主要国家进行的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 数据分析
    • 数据检验
    • 研究途径
  • 研究材料
    • 主要研究资料
    • 次级研究资讯来源
    • 先决条件

第三章市场走势分析

  • 驱动程式
  • 抑制因素
  • 机会
  • 威胁
  • 技术分析
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • COVID-19的影响

第四章 波特五力分析

  • 供应商的议价能力
  • 买方的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

5. 全球梅毒检测市场类型

  • 一期梅毒
  • 二期梅毒
  • 先天性梅毒
  • 潜伏梅毒
  • 其他类型

6. 全球梅毒检测市场（依检测地点划分）

  • 实验室检测
  • 在家测试
  • 就地检验

7. 全球梅毒检测市场（按技术）

  • 免疫检测
  • 分子诊断
  • 復用平台
  • 其他技术

8. 全球梅毒检测市场（依分销管道）

  • 直销
  • 网路药局
  • 零售药局

9. 全球梅毒检测市场（按应用）

  • 医院
  • 诊所
  • 公共卫生项目
  • 诊断实验室
  • 其他用途

第 10 章全球梅毒检测市场（以最终用户划分）

  • 公共医疗机构
  • 私人医疗机构
  • 非政府组织和社区健康中心
  • 其他最终用户

第 11 章。全球梅毒检测市场（按地区）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十二章 重大进展

  • 协议、伙伴关係、合作和合资企业
  • 收购与合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十三章：企业概况

  • Abbott Laboratories
  • SD Biosensor
  • Roche Diagnostics
  • Trinity Biotech
  • Siemens Healthineers
  • MedMira Inc.
  • Thermo Fisher Scientific
  • Fujirebio
  • Bio-Rad Laboratories
  • QuidelOrtho Corporation
  • Danaher Corporation
  • bioMerieux
  • Becton, Dickinson and Company（BD）
  • OraSure Technologies
  • Hologic Inc.
Product Code: SMRC31141

According to Stratistics MRC, the Global Syphilis Testing Market is accounted for $2.49 billion in 2025 and is expected to reach $4.49 billion by 2032 growing at a CAGR of 8.8% during the forecast period. Syphilis testing refers to clinical procedures aimed at identifying infection caused by Treponema pallidum, the bacterium that leads to syphilis. Diagnostic methods typically include blood-based non-treponemal and treponemal tests, which help determine disease stage, verify infection, and track patient response to treatment. This testing is vital for reducing disease spread, protecting maternal and infant health, and managing complications. It is particularly significant for individuals at higher risk or with possible exposure to sexually transmitted infections.

Market Dynamics:

Driver:

Increased routine screening programs

The rising implementation of routine syphilis screening initiatives is significantly boosting market demand. Public health agencies are intensifying efforts to detect infections early, especially among high-risk populations such as pregnant women and individuals with HIV. Technological advancements in rapid point-of-care tests are enabling broader deployment across clinics and outreach settings. Integration with digital health platforms is streamlining patient tracking and follow-up diagnostics. Emerging trends include AI-assisted screening algorithms and mobile-based testing kits that improve accessibility. As governments expand STI surveillance programs, syphilis testing is becoming a core component of preventive healthcare strategies.

Restraint:

Inadequate healthcare infrastructure and access

Many low-income countries face shortages in trained personnel, laboratory capacity, and essential testing supplies. Infrastructure gaps are especially pronounced in antenatal care settings, where early detection of congenital syphilis is critical. The lack of digital connectivity further restricts integration with centralized health systems. While mobile clinics and telemedicine offer partial solutions, scalability remains a challenge. Without sustained investment in healthcare infrastructure, syphilis testing coverage will remain uneven across geographies.

Opportunity:

Integration of multiplex and dual-purpose tests

Dual-purpose assays that detect multiple STIs simultaneously are gaining traction in both clinical and public health settings. These platforms reduce turnaround time, improve cost-efficiency, and enhance patient compliance. Advances in microfluidics and biosensor technologies are enabling compact, multi-analyte devices suitable for decentralized use. Regulatory bodies are increasingly supporting bundled testing protocols to streamline care delivery. As personalized medicine evolves, multiplex syphilis tests are expected to play a pivotal role in integrated sexual health diagnostics.

Threat:

Competition from other STI diagnostics

Tests for HIV, chlamydia, and gonorrhea often dominate procurement budgets and public health priorities. Multi-pathogen panels may dilute focus on syphilis-specific innovations unless bundled strategically. Rapid developments in molecular diagnostics and CRISPR-based detection are shifting attention toward newer technologies. Market fragmentation is also driven by regional preferences for certain test formats or brands.

Covid-19 Impact

The pandemic disrupted routine STI screening programs, leading to delayed diagnoses and reduced testing volumes. Lockdowns and resource reallocation toward Covid-19 diagnostics strained laboratory capacity and supply chains. However, the crisis accelerated adoption of remote testing kits and digital reporting platforms for STIs. Emergency regulatory pathways enabled faster approval of novel syphilis assays, including self-testing formats. Post-pandemic strategies now emphasize resilience, decentralized diagnostics, and integration with pandemic preparedness frameworks.

The congenital syphilis segment is expected to be the largest during the forecast period

The congenital syphilis segment is expected to account for the largest market share during the forecast period, due to its critical public health implications. Rising maternal screening mandates and improved prenatal care protocols are driving demand for early detection tools. Technological advances in rapid treponemal tests are enabling timely intervention during pregnancy. Governments are prioritizing congenital syphilis elimination through targeted funding and surveillance programs. Integration with electronic health records is improving case tracking and follow-up treatment. As awareness grows, congenital syphilis testing is becoming a cornerstone of maternal and neonatal health strategies.

The public health programs segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the public health programs segment is predicted to witness the highest growth rate, driven by expanding STI control initiatives worldwide. National and regional campaigns are scaling up syphilis screening through mobile units, community outreach, and school-based interventions. Adoption of cloud-based data systems is enhancing program monitoring and epidemiological insights. Innovations in low-cost, high-throughput testing platforms are making mass screening more feasible. Partnerships between NGOs, governments, and diagnostic firms are accelerating deployment in high-burden areas. As global health priorities shift toward STI elimination, public health programs will be central to market expansion.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share supported by rising healthcare investments and population-wide screening efforts. Countries like China, India, and Indonesia are scaling up STI diagnostics through national health missions and digital health rollouts. Local manufacturing of test kits is improving affordability and supply chain resilience. Emerging trends include AI-powered diagnostic platforms and mobile testing labs tailored for remote regions. Strategic collaborations between global and regional players are enhancing technology transfer and market penetration.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, fuelled by technological leadership and robust public health infrastructure. The U.S. and Canada are investing heavily in next-gen STI diagnostics, including molecular and AI-enhanced platforms. Regulatory agencies are streamlining approvals for innovative syphilis tests, including home-based and telehealth-compatible formats. Integration with electronic medical records and predictive analytics is improving case management and outbreak response. Reimbursement frameworks are increasingly supportive of routine STI screening, especially in underserved communities.

Key players in the market

Some of the key players profiled in the Syphilis Testing Market include Abbott Laboratories, SD Biosensor, Roche Diagnostics, Trinity Biotech, Siemens Healthineers, MedMira Inc., Thermo Fisher Scientific, Fujirebio, Bio-Rad Laboratories, QuidelOrtho Corporation, Danaher Corporation, bioMerieux, Becton, Dickinson and Company (BD), OraSure Technologies, and Hologic Inc.

Key Developments:

In September 2025, Roche announced that it has entered into a definitive merger agreement to acquire 89bio, Inc. a publicly listed clinical-stage biopharmaceutical company pioneering the development of innovative therapies for the treatment of liver and cardiometabolic diseases. 89bio's pegozafermin is a FGF21 analog currently in late-stage development for MASH.

In February 2025, Abbott and Shedd Aquarium are announcing one of Shedd's largest corporate gifts in recent history a $10 million pledge from Abbott and Abbott's philanthropic foundation, Abbott Fund. The investment cements the longstanding partnership between Shedd, Abbott, and Abbott Fund to enrich the cultural, educational and environmental fabric of Chicago and spark passion for protecting the ocean environment.

Types Covered:

  • Primary Syphilis
  • Secondary Syphilis
  • Congenital Syphilis
  • Latent Syphilis
  • Other Types

Location of Testings Covered:

  • Laboratory-Based Testing
  • Home-Based Testing
  • Point-of-Care Testing

Technologies Covered:

  • Immunoassay
  • Molecular Diagnostics
  • Multiplex Platforms
  • Other Technologies

Distribution Channels Covered:

  • Direct Sales
  • Online Pharmacies
  • Retail Pharmacies

Applications Covered:

  • Hospitals
  • Clinics
  • Public Health Programs
  • Diagnostic Laboratories
  • Other Applications

End Users Covered:

  • Public Healthcare Facilities
  • Private Healthcare Providers
  • NGOs and Community Health Centers
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Syphilis Testing Market, By Type

  • 5.1 Introduction
  • 5.2 Primary Syphilis
  • 5.3 Secondary Syphilis
  • 5.4 Congenital Syphilis
  • 5.5 Latent Syphilis
  • 5.6 Other Types

6 Global Syphilis Testing Market, By Location of Testing

  • 6.1 Introduction
  • 6.2 Laboratory-Based Testing
  • 6.3 Home-Based Testing
  • 6.4 Point-of-Care Testing

7 Global Syphilis Testing Market, By Technology

  • 7.1 Introduction
  • 7.2 Immunoassay
  • 7.3 Molecular Diagnostics
  • 7.4 Multiplex Platforms
  • 7.5 Other Technologies

8 Global Syphilis Testing Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Direct Sales
  • 8.3 Online Pharmacies
  • 8.4 Retail Pharmacies

9 Global Syphilis Testing Market, By Application

  • 9.1 Introduction
  • 9.2 Hospitals
  • 9.3 Clinics
  • 9.4 Public Health Programs
  • 9.5 Diagnostic Laboratories
  • 9.6 Other Applications

10 Global Syphilis Testing Market, By End User

  • 10.1 Introduction
  • 10.2 Public Healthcare Facilities
  • 10.3 Private Healthcare Providers
  • 10.4 NGOs and Community Health Centers
  • 10.5 Other End Users

11 Global Syphilis Testing Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Abbott Laboratories
  • 13.2 SD Biosensor
  • 13.3 Roche Diagnostics
  • 13.4 Trinity Biotech
  • 13.5 Siemens Healthineers
  • 13.6 MedMira Inc.
  • 13.7 Thermo Fisher Scientific
  • 13.8 Fujirebio
  • 13.9 Bio-Rad Laboratories
  • 13.10 QuidelOrtho Corporation
  • 13.11 Danaher Corporation
  • 13.12 bioMerieux
  • 13.13 Becton, Dickinson and Company (BD)
  • 13.14 OraSure Technologies
  • 13.15 Hologic Inc.

List of Tables

  • Table 1 Global Syphilis Testing Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Syphilis Testing Market Outlook, By Type (2024-2032) ($MN)
  • Table 3 Global Syphilis Testing Market Outlook, By Primary Syphilis (2024-2032) ($MN)
  • Table 4 Global Syphilis Testing Market Outlook, By Secondary Syphilis (2024-2032) ($MN)
  • Table 5 Global Syphilis Testing Market Outlook, By Congenital Syphilis (2024-2032) ($MN)
  • Table 6 Global Syphilis Testing Market Outlook, By Latent Syphilis (2024-2032) ($MN)
  • Table 7 Global Syphilis Testing Market Outlook, By Other Types (2024-2032) ($MN)
  • Table 8 Global Syphilis Testing Market Outlook, By Location of Testing (2024-2032) ($MN)
  • Table 9 Global Syphilis Testing Market Outlook, By Laboratory-Based Testing (2024-2032) ($MN)
  • Table 10 Global Syphilis Testing Market Outlook, By Home-Based Testing (2024-2032) ($MN)
  • Table 11 Global Syphilis Testing Market Outlook, By Point-of-Care Testing (2024-2032) ($MN)
  • Table 12 Global Syphilis Testing Market Outlook, By Technology (2024-2032) ($MN)
  • Table 13 Global Syphilis Testing Market Outlook, By Immunoassay (2024-2032) ($MN)
  • Table 14 Global Syphilis Testing Market Outlook, By Molecular Diagnostics (2024-2032) ($MN)
  • Table 15 Global Syphilis Testing Market Outlook, By Multiplex Platforms (2024-2032) ($MN)
  • Table 16 Global Syphilis Testing Market Outlook, By Other Technologies (2024-2032) ($MN)
  • Table 17 Global Syphilis Testing Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 18 Global Syphilis Testing Market Outlook, By Direct Sales (2024-2032) ($MN)
  • Table 19 Global Syphilis Testing Market Outlook, By Online Pharmacies (2024-2032) ($MN)
  • Table 20 Global Syphilis Testing Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
  • Table 21 Global Syphilis Testing Market Outlook, By Application (2024-2032) ($MN)
  • Table 22 Global Syphilis Testing Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 23 Global Syphilis Testing Market Outlook, By Clinics (2024-2032) ($MN)
  • Table 24 Global Syphilis Testing Market Outlook, By Public Health Programs (2024-2032) ($MN)
  • Table 25 Global Syphilis Testing Market Outlook, By Diagnostic Laboratories (2024-2032) ($MN)
  • Table 26 Global Syphilis Testing Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 27 Global Syphilis Testing Market Outlook, By End User (2024-2032) ($MN)
  • Table 28 Global Syphilis Testing Market Outlook, By Public Healthcare Facilities (2024-2032) ($MN)
  • Table 29 Global Syphilis Testing Market Outlook, By Private Healthcare Providers (2024-2032) ($MN)
  • Table 30 Global Syphilis Testing Market Outlook, By NGOs and Community Health Centers (2024-2032) ($MN)
  • Table 31 Global Syphilis Testing Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.